{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:02:56Z","timestamp":1790229776912,"version":"4.1.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010104","name":"Tianjin Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Engineered bacteria and engineered probiotics are emerging living therapeutic platforms for intestinal diseases, supported by advances in synthetic biology, genetic engineering, and microbiome technologies. This study aimed to characterize the research landscape, knowledge structure, research hotspots, and emerging trends of engineered bacteria and engineered probiotics for intestinal disease therapy using bibliometric and knowledge mapping approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications were retrieved from the Web of Science Core Collection and Scopus databases. After publication type restriction, thematic relevance screening, database merging, and duplicate removal, 499 publications published between 2015 and 2026 were included. The search was completed on July 3, 2026; therefore, records from 2026 represent a partial-year dataset. R, Python, VOSviewer, and CiteSpace were used to analyze annual publication trends, country\/region, institution, author and journal distributions, keyword co-occurrence and bursts, co-cited references, and research frontiers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Publication output increased markedly over the study period, reaching 109 publications in 2025; 64 records were retrieved for 2026 by the cutoff date. China had the highest publication output, whereas the United States had the highest total link strength, and Asia contributed 361 publications. Keyword analysis identified inflammatory bowel disease, gut microbiota, probiotics, engineered bacteria, engineered probiotics, synthetic biology, intestinal barrier, drug delivery, colorectal cancer, and immunotherapy as major research hotspots. Co-cited reference and timeline analyses indicated a shift in research attention from conventional probiotic-mediated anti-inflammatory effects, mucosal immune regulation, and intestinal barrier protection toward bacterial chassis selection, enhanced colonization, self-regulated genetic circuits, probiotic-based biomaterials, sustained-release delivery systems, and engineered bacteria-mediated antitumor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The bibliometric evidence indicates that recent research attention is increasingly focused on programmable living therapeutic strategies. Environmental sensing, local therapeutic delivery, sustained activity, and multifunctional design features are capabilities reported in the underlying literature and represented among the emerging themes identified in this analysis, rather than therapeutic performance directly established by the bibliometric data. Future research should further address biosafety, genetic stability, spatiotemporal controllability, intestinal colonization, delivery efficiency, and clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1970221","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:44:52Z","timestamp":1790228692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineered bacteria and engineered probiotics for intestinal disease therapy: a bibliometric and knowledge mapping analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Medical Center of the Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyue","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.3390\/ijms21103615","article-title":"Production and sensing of butyrate in a probiotic Escherichia coli strain","volume":"21","author":"Bai","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1162\/qss_a_00018","article-title":"Web of science as a data source for research on scientific and scholarly activity","volume":"1","author":"Birkle","year":"2020","journal-title":"Quant. Sci. Stud."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41522-026-01011-w","article-title":"Genetically engineered probiotic E. coli Nissle 1917 enhances protection against Salmonella via increased adhesion and systemic T-cell responses","volume":"12","author":"Carolak","year":"2026","journal-title":"NPJ Biofilms Microbiom."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-020-15508-1","article-title":"Developing a new class of engineered live bacterial therapeutics to treat human diseases","volume":"11","author":"Charbonneau","year":"2020","journal-title":"Nat. Commun."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.smim.2017.09.006","article-title":"Microbiome, inflammation and colorectal cancer","volume":"32","author":"Chen","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","article-title":"Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat. Commun."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41591-019-0498-z","article-title":"Programmable bacteria induce durable tumor regression and systemic antitumor immunity","volume":"25","author":"Chowdhury","year":"2019","journal-title":"Nat. Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1021\/acsbiomaterials.2c00202","article-title":"An engineered probiotic produces a type III interferon IFNL1 and reduces inflammations in in vitro inflammatory bowel disease models","volume":"9","author":"Chua","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref10","article-title":"Confirmatory clinical study in active ulcerative colitis (StarFish-UC) (NCT07296315)","year":"2026"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jconrel.2012.06.003","article-title":"Microencapsulation of probiotics for gastrointestinal delivery","volume":"162","author":"Cook","year":"2012","journal-title":"J. Control. Release"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41573-021-00285-3","article-title":"Engineering living therapeutics with synthetic biology","volume":"20","author":"Cubillos-Ruiz","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature18930","article-title":"Synchronized cycles of bacterial lysis for in vivo delivery","volume":"536","author":"Din","year":"2016","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijpharm.2017.07.068","article-title":"Targeted delivery of probiotics to enhance gastrointestinal stability and intestinal colonisation","volume":"530","author":"Dodoo","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1038\/s41467-020-20200-5","article-title":"Receptor-targeted engineered probiotics mitigate lethal Listeria infection","volume":"11","author":"Drolia","year":"2020","journal-title":"Nat. Commun."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"5","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"626349","DOI":"10.3389\/fonc.2021.626349","article-title":"The role of gut barrier dysfunction and microbiome Dysbiosis in colorectal Cancer development","volume":"11","author":"Genua","year":"2021","journal-title":"Front. Oncol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymben.2023.09.008","article-title":"Metabolic engineering of commensal bacteria for gut butyrate delivery and dissection of host-microbe interaction","volume":"80","author":"Gong","year":"2023","journal-title":"Metab. Eng."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.chom.2024.07.028","article-title":"Engineered probiotic ameliorates ulcerative colitis by restoring gut microbiota and redox homeostasis","volume":"32","author":"Guo","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"eaax0876","DOI":"10.1126\/scitranslmed.aax0876","article-title":"Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies","volume":"12","author":"Gurbatri","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1021\/acssynbio.2c00314","article-title":"Intestinal engineered probiotics as living therapeutics: chassis selection, colonization enhancement, gene circuit design, and biocontainment","volume":"11","author":"Huang","year":"2022","journal-title":"ACS Synth. Biol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nbt.4222","article-title":"Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria","volume":"36","author":"Isabella","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ymben.2021.10.005","article-title":"Engineering Bacteroides thetaiotaomicron to produce non-native butyrate based on a genome-scale metabolic model-guided design","volume":"68","author":"Kim","year":"2021","journal-title":"Metab. Eng."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.tmed.2026.100018","article-title":"Single-cell encapsulation of Agathobacter rectalis in Aloe vera gel alleviates DSS-induced colitis by remodeling the gut microbiota-metabolite axis","volume":"1","author":"Li","year":"2026","journal-title":"TransMed"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12934-017-0762-1","article-title":"Lactobacillus delivery of bioactive interleukin-22","volume":"16","author":"Lin","year":"2017","journal-title":"Microb. Cell Factories"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41467-023-37225-1","article-title":"Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field","volume":"14","author":"Ma","year":"2023","journal-title":"Nat. Commun."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s12276-020-00507-5","article-title":"Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice","volume":"52","author":"Namai","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref28","year":"2024"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1038\/s41467-023-39224-8","article-title":"Bioengineering of bacteria for cancer immunotherapy","volume":"14","author":"Nguyen","year":"2023","journal-title":"Nat. Commun."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/procel\/pwaf085","article-title":"Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives","volume":"17","author":"Niu","year":"2026","journal-title":"Protein Cell"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cels.2018.06.008","article-title":"Synthetic biology and engineered live biotherapeutics: toward increasing system complexity","volume":"7","author":"Ozdemir","year":"2018","journal-title":"Cell Syst"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.14207\/ejsd.2021.v10n1p303","article-title":"Mapping the literature on sustainability reporting: a bibliometric analysis grounded in Scopus and web of science core collection","volume":"10","author":"Pasko","year":"2021","journal-title":"Eur. J. Sustain. Dev."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1038\/s41467-019-13336-6","article-title":"Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut","volume":"10","author":"Praveschotinunt","year":"2019","journal-title":"Nat. Commun."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrmicro.2017.172","article-title":"Engineering bacteria for diagnostic and therapeutic applications","volume":"16","author":"Riglar","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1000873","DOI":"10.3389\/fbioe.2022.1000873","article-title":"Microbiome engineering: engineered live biotherapeutic products for treating human disease","volume":"10","author":"Rutter","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1021\/acsabm.5c00959","article-title":"Probiotic Bacteria as therapeutics and biohybrid drug carriers: advances, design strategies, and future outlook","volume":"8","author":"Sahoo","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.7150\/thno.103983","article-title":"Engineered probiotic-based biomaterials for inflammatory bowel disease treatment","volume":"15","author":"Sang","year":"2025","journal-title":"Theranostics"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-042320-021020","article-title":"The gut microbiome and inflammatory bowel diseases","volume":"73","author":"Shan","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.289.5483.1352","article-title":"Treatment of murine colitis by Lactococcus lactis secreting interleukin-10","volume":"289","author":"Steidler","year":"2000","journal-title":"Science"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e038163","DOI":"10.1136\/bmjopen-2020-038163","article-title":"Does geographical variation confound the relationship between host factors and the human gut microbiota: a population-based study in China","volume":"10","author":"Sun","year":"2020","journal-title":"BMJ Open"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"819336","DOI":"10.3389\/fmicb.2022.819336","article-title":"Probiotic Escherichia coli Nissle 1917 expressing Elafin protects against inflammation and restores the gut microbiota","volume":"13","author":"Teng","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref43","year":"2016"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/mi.2009.116","article-title":"Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis","volume":"3","author":"Vandenbroucke","year":"2010","journal-title":"Mucosal Immunol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/1756283X16644242","article-title":"The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions","volume":"9","author":"Vindigni","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1021\/acssynbio.4c00036","article-title":"Engineering a novel probiotic toolkit in Escherichia coli Nissle 1917 for sensing and mitigating gut inflammatory diseases","volume":"13","author":"Weibel","year":"2024","journal-title":"ACS Synth. Biol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-019-0406-6","article-title":"Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer","volume":"25","author":"Wirbel","year":"2019","journal-title":"Nat. Med."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1027448","DOI":"10.3389\/fcimb.2022.1027448","article-title":"Research trends on the relationship between gut microbiota and colorectal cancer: a bibliometric analysis","volume":"12","author":"Wu","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00253-024-13163-w","article-title":"Dual engineered bacteria improve inflammatory bowel disease in mice","volume":"108","author":"Wu","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1021\/acsmacrolett.5c00295","article-title":"Engineered probiotics for colitis therapy by improving intestinal colonization and scavenging ROS","volume":"14","author":"Yuan","year":"2025","journal-title":"ACS Macro Lett."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1264705","DOI":"10.3389\/fimmu.2023.1264705","article-title":"Emerging insights into inflammatory bowel disease from the intestinal microbiota perspective: a bibliometric analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1038\/s41467-022-31171-0","article-title":"Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat. Commun."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1865862","DOI":"10.3389\/fimmu.2026.1865862","article-title":"Engineered Escherichia coli Nissle 1917 secreting anti-TNF-\u03b1 nanobody as a single-strain live biotherapeutic for inflammatory bowel disease","volume":"17","author":"Zhu","year":"2026","journal-title":"Front. Immunol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1794032","DOI":"10.3389\/fmicb.2026.1794032","article-title":"Bibliometric analysis of genetically engineered bacteria in tumor therapy","volume":"17","author":"Zhu","year":"2026","journal-title":"Front. Microbiol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"100167","DOI":"10.1016\/j.engmic.2024.100167","article-title":"Genetically engineered bacteria as inflammatory bowel disease therapeutics","volume":"4","author":"Zou","year":"2024","journal-title":"Engin. Microbiol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1970221\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:44:53Z","timestamp":1790228693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1970221\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":55,"alternative-id":["10.3389\/fmicb.2026.1970221"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1970221","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1970221"}}